Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

Instead of diversifying across diseases, Kenai is building deep expertise in Parkinson's. Its pipeline addresses different patient needs: replacing lost cells (lead program), repairing existing damaged cells (002), and targeting inherited forms (003), creating a comprehensive disease franchise.

For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

Coya Therapeutics' vision is to make diseases like ALS "livable" by completely stopping their progression. This ambitious goal stems from a small investigator-initiated trial where patients showed no disease progression over six months, a period where a significant decline is typically expected, reframing the therapeutic benchmark.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

While designed for the 10% of Parkinson's patients with a specific genetic variant, Gain Therapeutics' trial data shows its drug may benefit a larger group. About 50% of patients without the gene defect also have the toxic lipid buildup the drug targets, suggesting a significantly expanded potential market beyond the initial niche population.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.